INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's Disease

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom(TM) for RDEB
INmune Bio Advances CORDStrom(TM) Towards UK Marketing Authorization in RDEB
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom(TM) Platform
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.